

Review

Cellular pathology induced by snake venom phospholipase A₂ myotoxins and neurotoxins: common aspects of their mechanisms of action

C. Montecucco⁺, J. M. Gutiérrez and B. Lomonte

Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José 2060 (Costa Rica),
e-mail: cesare.montecucco@unipd.it, jgutierrez@icp.ucr.ac.cr, blomonte@cariari.ucr.ac.cr

Received 05 March 2008; received after revision 08 April 2008; accepted 29 April 2008
Online First 20 June 2008

Abstract. A large variety of snake toxins evolved from PLA₂ digestive enzymes through a process of ‘accelerated evolution’. These toxins have different tissue targets, membrane receptors and mechanisms of alteration of the cell plasma membrane. Two of the most commonly induced effects by venom PLA₂s are neurotoxicity and myotoxicity. Here, we will discuss how these snake toxins achieve a similar cellular lesion, which is evolutionarily highly conserved, despite the differences listed above. They cause an

initial plasma membrane perturbation which promotes a large increase of the cytosolic Ca²⁺ concentration leading to cell degeneration, following modes that we discuss in detail for muscle cells and for the neuromuscular junction. The different systemic pathophysiological consequences caused by these toxins are not due to different mechanisms of cell toxicity, but to the intrinsic anatomical and physiological properties of the targeted tissues and cells.

Keywords. Snake venoms, PLA₂, neurotoxins, myotoxins, Ca²⁺.

Introduction

Hundreds of species of venomous snakes with a wide variety of prey produce venoms which contain varying proportions of toxins endowed with phospholipase A₂ (PLA₂) activity. These proteins have evolved from an ancestral PLA₂ with digestive function. They fold very similarly and display a range of enzymatic turnover values from zero to the high values typical of digestive enzymes such as those found in pancreatic secretions. These toxins are produced by the snake venom gland and, when injected in the prey (usually in large muscles or subcutaneously), cause a range of patho-

logical alterations. Some PLA₂ toxins act specifically on the peripheral nervous system and paralyse the prey within very short time periods; others target both the nervous and the muscular systems, and a large number act mainly on skeletal muscles causing extensive damage (myotoxins); still others exert various effects, such as anticoagulation, or affect platelet aggregation, hypotension, hemolysis and edema [1].

Neurotoxins produced by elapid snakes (β-bungarotoxin, taipoxin, textilotoxin etc.) are the main, or the sole, responsible for the death of the prey. These neurotoxins exert their action at peripheral nerve terminals [2]. Death usually follows respiratory paralysis with little or no damage to other organs [3,4]. However, if the patient’s respiration is mechanically

⁺ Permanent address: Dipartimento di Scienze Biomediche, Università di Padova, 35121 Padova (Italy).

Table 1. Some properties of selected^a snake PLA₂ and PLA₂-homologue toxins.

Toxin name	Snake species	Structural group	Number of subunits	Sequence code	PDB code	Lethal potency ^b	PLA ₂ activity ^c	References
Neurotoxic PLA₂s								
ammodytoxin A	<i>Vipera ammodytes</i>	IIa	1	P00626	n.d.	21 iv	280	[138]
β-bungarotoxin	<i>Bungarus multicinctus</i>	Ia	2	P00617/P00989	2NBT	19 ip	61	[139–141]
taipoxin	<i>Oxyuranus scutellatus</i>	Ia	3	P00614/-15/-16	n.d.	2 iv	0.4	[142]
textilotoxin	<i>Pseudonaja textilis</i>	Ia	5	P23026/-27/-28/P30811	n.d.	1 iv	3.2	[143]
Neurotoxic and myotoxic PLA₂s								
notexin	<i>Notechis scutatus</i>	Ia	1	P00608	1AE7	17 iv	1390	[144–145]
crototoxin	<i>Crotalus d. terrificus</i>	IIa	2	P08878/P62022	2QOG	110 iv	85	[146–147]
Myotoxic D49 PLA₂s								
myotoxin III	<i>Bothrops asper</i>	IIa	2	P20474	n.d.	470 iv	750	[148]
bothropstoxin II	<i>Bothrops jararacussu</i>	IIa	2	n.a.	n.d.	n.d.	27	[149]
Myotoxic PLA₂ homologues								
AppK49	<i>Agkistrodon p. piscivorus</i>	IIa	1	P04361	1PPA	25000 iv	- K49 ^d	[150–152]
ACL myotoxin	<i>A. contortrix laticinctus</i>	IIa	1	AAC59887	1S8G	n.d.	- K49	[96,153,154]
myotoxin II	<i>Atropoides nummifer</i>	IIa	2	P82950	2AOZ	n.d.	- K49	[155–157]
myotoxin II	<i>Bothrops asper</i>	IIa	2	P24605	1CLP	n.d.	- K49	[158–160]
bothropstoxin I	<i>Bothrops jararacussu</i>	IIa	2	Q90249	2H8I	4800 iv	- K49	[161–163]
myotoxin II	<i>Bothrops moojeni</i>	IIa	2	Q9I834	1XXS	7600 ip	- K49	[164–166]
ammodytin L	<i>Vipera ammodytes</i>	IIa	1	P17935	n.d.	3600 ip	- S49	[47, 167]

^a A few representatives out of the large number of snake PLA₂ toxins were selected on the basis of most available structural and functional information.

^b Mouse LD₅₀ in µg/kg, by intravenous (iv) or intraperitoneal (ip) routes.

^c µmol/min/mg toxin.

^d All PLA₂ homologues are here considered to be enzymatically inactive, residue at position 49 is indicated by single letter.

n.d.: not determined; n.a.: not available.

supported, very frequently there is a complete recovery. Venom PLA₂s may also induce 'central neurotoxicity' when administered by intracerebroventricular injection [5]. However, since PLA₂s do not cross the blood-brain barrier, this effect is unlikely to be pathologically relevant and, therefore, only peripheral neurotoxicity will be discussed in this review.

Some neurotoxic PLA₂s also affect the skeletal muscles, as in the case of notexin and crototoxin [2] (and Table 1). In general, they cause extensive and irreversible damage to skeletal muscle. These toxins usually induce a systemic myotoxicity, *i.e.* rhabdomyolysis, with impressive increments in plasma creatine kinase (CK) and other muscle-derived enzymes, and with myoglobinuria, often leading to acute renal failure and hyperkalemia [6]. The ability of these PLA₂s to induce systemic myotoxicity is directly related to their high selectivity for targets in muscle cells and, in some cases, in nerve terminals. Accordingly, these toxins do not induce cytotoxicity when incubated with other cell types or with immature muscle cell precursors, *i.e.* myoblasts [7]. This is in contrast with other PLA₂s that induce mostly local myotoxicity, and are capable of lysing many different cell types [8, 9] (see below). Invariably, all the myotoxic PLA₂s cause an extensive inflammatory reaction which develops following necrosis itself and as a consequence of their direct action on inflammatory cells; they are also able to induce prominent

pain, *i.e.* hyperalgesia and allodynia [10]. In the case of viperid snake venoms, the local pathology induced by PLA₂s is further complicated by the action of other toxic components, mostly zinc-dependent metalloproteinases, which cause haemorrhages, blistering and other alterations responsible for extensive tissue damage and sequelae due to poor tissue regeneration. Moreover, toxin-induced tissue damage favours infection by bacteria [11], which further complicates the local pathology and may end up in gangrene and tissue loss requiring amputation of the affected limb [6].

The ensemble of these PLA₂ toxins is intensively studied because envenomings constitute a major health problem in many countries [12]. On the other hand, toxins are also studied because they may help to reveal unknown aspects of tissue and cell physiology [13]. This review will not provide an extensive coverage of the vast literature on these snake toxins, as this was recently done for the myotoxins [14] and for the neurotoxins [15, 16]. Rather, we intend to review and discuss the shared features in the structure and function of the snake PLA₂ toxins responsible for such diverse effects, in order to identify common steps in their molecular and cellular mode of action and to discuss them in relation to the specific pathologies they induce.




Figure 1. Three-dimensional structures of snake venom PLA₂s. Ribbon representations of (A) notexin (1AE7), a group I phospholipase A₂ from *Notechis scutatus scutatus* venom [145] and (B) D49 basic PLA₂ (1VAP), a group II enzyme from *Agkistrodon piscivorus piscivorus* venom [168]. Disulfide bonds are shown in stick representation. Superposition of both structures (C) illustrates the conservation in the calcium-binding loop and the three major helices (H1, H2, H3), despite evident deviations in the other interconnecting loops and the β -wing. Note the extended C-terminal in the group II enzymes (B) in comparison to group I (A). N- and C-termini are indicated by N and C, respectively.

Structure of snake PLA₂ toxins

The crystallographic structure of several snake PLA₂ toxins has been determined (structures at Protein Data Bank: <http://www.rcsb.org/pdb/>). Secreted PLA₂s fold very similarly in a characteristic scaffold consisting of four main helices held together by seven intrachain disulfide bonds (Fig. 1). These proteins vary in length (119–134 amino acids) and are flattened ellipsoids of approximate dimensions 45 × 30 × 20 Å. Two long antiparallel and disulfide-linked α -helices define an elongated and water-shielded ‘hydrophobic channel’, which leads the phospholipid substrate to the catalytic site; this is characterized by the presence of four key residues: His48, Asp49, Tyr52 and Asp99. The His residue hydrogen-binds the water molecule used for hydrolysis, whilst Asp49 coordinates and positions the Ca²⁺ ion which binds and polarizes both the phosphate and the *sn*-2 carbonyl groups of the phospholipid molecule during hydrolysis. Another highly conserved region in PLA₂ is the ‘calcium-binding loop’, comprising residues Tyr28, Gly30 and Gly32 which, in combination with Asp49, binds the Ca²⁺ ion required for catalysis. In addition, there is an ‘interfacial binding surface’, which mediates the adsorption of the enzyme onto the lipid-water interface of the phospholipid membrane bilayer, strongly promoted by anionic amphipatic molecules such as fatty acids (FAs) [17]. These general features are common to both group I and group II venom PLA₂s, which mainly differ in the position of one of their seven disulfide bonds, by the presence of the ‘pancreatic loop’ in some of group I enzymes and by an extended C-terminal loop in the group II counterparts [17].

A distinct subgroup of PLA₂ homologue toxins present the replacement of the key Asp49 residue with a Lys, Arg, Ser Gln, or Asn residue, among other substitutions, with the consequent loss of Ca²⁺-binding and enzymatic activity. The most abundant of these catalytically inert proteins correspond to the myotoxic Lys49 PLA₂ homologues [18]. The major toxicity-determining site in these PLA₂ homologues encompasses residues 115–129 in the C-terminal region, which includes a variable combination of positively charged and hydrophobic/aromatic residues, with the ability to alter the bilayer membrane integrity [18, 19]. The widespread occurrence of these PLA₂ homologues in viperid venoms is intriguing from the molecular evolutionary standpoint, since evidently they diverged from a gene encoding catalytically active variants and must play a relevant adaptive role, as judged by their abundance in many venoms. The nature of this role remains, however, poorly understood.

Many myotoxic and neurotoxic PLA₂s are monomers, although oligomerization, particularly dimerization, is not uncommon in these proteins (Table 1). Several neurotoxins include additional subunits, such as a disulfide-linked K⁺ channel-binding subunit in the case of β -bungarotoxin [20]. Taipoxin contains two additional PLA₂ subunits with no catalytic activity, and textilotoxin consists of five subunits, only one of which has PLA₂ activity [1]. Crotoxin is a heterodimer of a toxic PLA₂ subunit and of a non-toxic smaller subunit termed crotopotin or subunit A, which results from the proteolytic processing of a PLA₂ chain, and has been described as an enhancer of the toxicity of the PLA₂ subunit [21]. Alternatively, it has been suggested that oligomerization is an evolutionary strategy to increase the binding affinity and specificity

of a toxin for a defined target such as the motoneuron endplate [22].

Steps involved in the cellular toxicity of snake PLA₂ toxins

Distribution

The available experimental data indicate that cell intoxication by snake PLA₂ myotoxins and neurotoxins can be divided into several steps. The distribution of different toxins within the injected animal body appears to vary substantially from one toxin to the other, and two groups of toxins can be broadly identified. The systemically-acting group, which includes the neurotoxins and systemic myotoxins, and the locally-acting myotoxins, which induce only moderate elevations of plasma CK activity and do not cause myoglobinuria and systemic myonecrosis [23–25]. Although part of the action of the first group of toxins is displayed close to the site of injection, on adjacent skeletal muscles and neuromuscular junctions (NMJs), clinical reports indicate that the neurotoxins are also capable of reaching distant anatomical loci, such as the respiratory muscles or facial muscles, after having been injected in a leg or foot [3,4]. Likewise, crotoxin, notexin and other systemically-acting PLA₂s are capable of inducing necrosis of distant muscles [26, 27]. However, PLA₂s toxins are unable to cross the blood-brain barrier and therefore do not reach the central nervous system. The molecular and physiological basis of this rapid toxin redistribution within the body of the prey is not known, though its evolutionary advantage is evident. At variance, the group of locally-acting toxins may do so because of their rapid binding to various components of the tissues where they are injected, thereby precluding their systemic distribution and restricting their action to the local scenario [25].

Cell binding

A first essential step in cell pathology is toxin binding to the target cells (Fig. 2). As crucial as this step is, it is the least understood in molecular terms. Notwithstanding the large amount of work done, for none of these snake toxins is the molecular identity of their functional receptors known, except for β-bungarotoxin which binds to K⁺ channels of the presynaptic membrane of peripheral nerves [15, 16, 28, 29]. Whilst both skeletal muscle cell lines and isolated muscle fibers are available for experimental studies, this is not the case of the peripheral motoneurons, which are the main targets of neurotoxins. Most research has been thus performed with brain homogenates and synaptosomes, and with primary cultures of neurons isolated

from the embryonic central nervous system; thus, the possibility that they are only partially relevant models for what happens *in vivo* should be considered. Indeed, β-bungarotoxin is rather specific for motor nerve terminals, whilst sensory discharges are not affected for several hours of incubation with the toxin. At variance, in the central nervous system this neurotoxin appears to bind more specifically to cholinergic and GABAergic terminals [30, 31]. Despite this limitation, these studies have indicated the presence of a limited number of high-affinity binding sites, mainly located at presynaptic nerve terminals [28, 31–33]. No competition among the different neurotoxins for binding to the presynaptic membrane was evidenced, indicating that they bind to different receptors.

Even less is known with respect to the receptors of myotoxic PLA₂s, although they appear to be expressed predominantly on the cell surface of differentiated myotubes and adult muscle fibers, but not in undifferentiated myoblasts [34, 35] because the former cells are toxin-sensitive, whilst the latter ones are more resistant to the action of these toxins, especially in the case of systemically-acting PLA₂s [7]. The selectivity for certain muscle cells is further evidenced by the preference of some systemically-acting myotoxins, like notexin and crotoxin, for type I muscle fibers [36, 37]. The binding of notexin to muscle cell plasma membrane has been documented by immunoelectron microscopy [37]. Furthermore, the ability of cyclosporin A, an inhibitor of calcineurin, to suppress the myotoxic action of crotoxin can be interpreted on the basis of the calcineurin-induced shift of muscle fiber type to crotoxin-susceptible type I, slow oxidative fibers [38]. However, the identity of receptors remains elusive. M-type PLA₂ receptor does not seem to be relevant for myotoxicity in the case of OS₂, an elapid PLA₂, and the myotoxic Lys49 PLA₂s do not bind to this receptor [39]. The recent finding of strong and specific binding of Lys49 PLA₂s to the VEGF receptor is intriguing, but the possible significance of this interaction in myotoxicity is unknown [40]. It is noteworthy, however, that binding of Lys49 PLA₂s to this receptor occurs through the C-terminal region, known to play a key role in plasma membrane perturbation [41]. It has been observed that negatively-charged lipids in the plasma membrane may play a role in the binding of some locally-acting myotoxic PLA₂s [42]. Thus, the nature and identity of myotoxic PLA₂ receptors in target cells remain as open questions.

The ensemble of these observations, together with the rapidity of the degenerative events occurring in muscle and nerves (within the range of seconds to




Figure 2. Schematic representation of the action of myotoxic and neurotoxic snake PLA₂s and PLA₂ homologues in skeletal muscle cells (A) and motor nerve terminals (B). (A) Myotoxic PLA₂s can be Asp49 catalytically-active variants or PLA₂ homologues devoid of enzymatic activity. Step (1) represents the myotoxins (left panel) or neurotoxins (right panel) binding to either to high-affinity specific protein receptors (R) or to low-affinity lipid domains of the plasma membrane. Step 2 is the hydrolysis of phospholipids that takes place for both neurotoxins (right panel) and PLA₂ active myotoxins (left panel). The enzymatically-inactive myotoxins act via direct perturbation of the membrane (left panel, step 3). Step 2 is in any case followed by alteration of the membrane structure. Steps 2 (both panels) and 3 (left panel) represent a perturbed plasma membrane which becomes permeable to ions, thus losing its membrane potential and allowing a large influx of Ca²⁺ from the extracellular medium. Such altered membrane promotes the exocytosis of ready-to-release synaptic vesicles (SV) at the nerve terminal (step 3, right panel). Step 4 in both panels represents a large increment in cytosolic Ca²⁺ concentration, which induces hypercontraction of myofilaments (step 5, left panel) and, in turn, may cause mechanical damage to the plasma membrane. In addition, membrane repair processes, depending on dysferlin, may take place by vesicle fusion to damaged membrane segments (arrow 11, left panel). The large increment of cytosolic Ca²⁺ causes the exocytosis of the reserve pool of synaptic vesicles (step 5, right panel). Ca²⁺ uptake by mitochondria, through the uniporter, results in mitochondrial swelling, disorganization of cristae, formation of hydroxyapatite crystals and flocculent densities, and opening of the permeability transition pore, thus resulting in a severe impairment of mitochondrial function (step 6, both panels). Ca²⁺-dependent proteinases (calpains) are activated (step 7, both panels) and degrade cytoskeletal components (step 8, both panels), further affecting the mechanical integration of the cell. Ca²⁺-dependent cytosolic PLA₂s are activated and promote further hydrolysis of intracellular membranes and plasma membrane (step 9, both panels). Plasma membrane disruption allows the entry of neurotoxins and, possibly, myotoxic PLA₂s (step 10, both panels), which hydrolyze and damage intracellular membrane systems, until inactivated by yet undetermined molecular events.

minutes), strongly suggest that the primary site of action of these PLA₂ toxins is the plasma membrane, and not an intracellular target. This does not exclude the possibility, reviewed recently [15], that at least some of these toxins enter the cell, further contributing to cell pathology with an intracellular action (Fig. 2). However, this entry is likely to occur after an

initial action on the plasma membrane which marks the onset of degenerative events. The present situation calls for more experimental efforts in order to identify the toxin receptors, which, in all likelihood, are physiologically-important molecules in the membranes of nerve terminals and muscle fibers, as they do not seem to be negatively selected by the evolu-

tionary pressure exerted by the toxin-producing snakes on their prey. That such evolution takes place is well illustrated by the development of resistance to α -bungarotoxin by mutation of its receptor, the nicotinic ACh receptor, in different animals [43, 44].

Membrane damage

Since the discovery of snake PLA₂ toxins, it was obvious to consider the possibility that they act via the hydrolysis of phospholipids of the plasma membrane, and a long list of studies were dedicated to test this possibility. Almost invariably, experimental designs have been directed to determine the consequences on toxicity of inactivating the enzymatic activity. Sr²⁺ and other divalent cations, which do not support the PLA₂ catalytic activity, replaced Ca²⁺ in the medium of isolated NMJ preparations or cells in culture [1, 15, 28]. In addition, chemical modifications of PLA₂ specific residues were used in other studies, and more recently this issue was approached by site-directed mutagenesis [39, 45–48]. In general, the reduction or abolition of PLA₂ activity of neurotoxins and myotoxins was correlated to a varying extent with loss of toxicity, but no conclusive evidence about the involvement of the PLA₂ activity in toxicity was obtained.

Direct approaches involving measurement of PLA₂ hydrolysis products in neurons and use of the hydrolysis products themselves were attempted only recently [49–51]. As this literature has been analysed in detail recently elsewhere [1, 15, 16], we would like to make here only a general, but substantial, summary, and then discuss the consequences of these findings. Clearly, PLA₂ activity cannot be directly involved in the action of the Lys49 myotoxins, and their mechanism of action will be discussed afterwards.

For the snake venom myotoxins and neurotoxins which are enzymatically active, the PLA₂-catalysed production of lysophospholipids (LysoPLs) and FAs is involved in membrane damage. However, this PLA₂ activity is not sufficient by itself, as toxicity is strictly associated with the precise site and mode of binding of each toxin to the membrane. In other words, it is the specific binding properties of each toxin that determine the localization and extent of the membrane damage caused by PLA₂ activity [16, 52, 53]. This knowledge helps to explain a puzzling aspect of the action of these neurotoxins, *i.e.* that there is no correlation between their PLA₂ activities *in vitro* and their toxicities [16] (Table 1). The two most potent PLA₂ neurotoxins are taipoxin and textilotoxin, which have the lowest *in vitro* PLA₂ activity (Table 1). However, if one assumes that they bind with high affinity and specificity to selected targets of the presynaptic membrane, then their damaging activity

is maximized as the phospholipid hydrolysis occurs at toxicology-relevant sites [52, 53]. These neurotoxins have been suggested to bind to the so-called active zones, *i.e.* those microdomains of the presynaptic membrane where synaptic vesicle neurotransmitter release takes place [16, 50, 53]. An alternative suggestion has been that they act on the internal membrane layer of synaptic vesicles, once they become exposed to the medium following exocytosis [54]. This strict connection between PLA₂ activity, specificity and affinity of binding also appears to be valid for the PLA₂ myotoxins that could bind to microdomains of the sarcolemma particularly sensitive to the presence of LysoPLs and FAs, or where their activity is maximized and causes relevant derangement to the plasma membrane organization.

What are the consequences of the toxin-catalysed conversion of phospholipids into LysoPLs and FAs to the membrane bilayer organization? This question can be answered on the basis of the molecular properties of LysoPLs and FAs with respect to those of phospholipids. In general, without going into the details of the different shapes of the various classes of phospholipids, they have a rather cylindrical shape with a balance between the hydrophilic head group and the hydrophobic fatty acid chains, as to be compatible with the formation of a bilayer membrane structure. LysoPLs have an inverted cone shape and a lower hydrophobic portion with respect to phospholipids; they spontaneously form spherical micelles in polar solvents. When they are comprised within bilayer biological membranes, they induce a positive curvature of the membrane layer where they are located; in the case of the toxins, this is the outer monolayer of the plasma membrane. Long-chain FAs are cone-shaped and hydrophobic, and at variance with LysoPLs, they have a high mobility such that they can rapidly move from one membrane layer to the other. This high flip-flop rate allows their rapid equilibration in the two layers of biological membranes. The presence of LysoPLs and FAs within the plasma membrane has three major consequences: a) it favours the membrane fusion of synaptic vesicles and inhibits the opposite process of endocytosis; b) it increases the membrane permeability to ions; and c) FAs may partition into intracellular organelles and alter their function, as depicted in Figure 2.

Why does the presence of LysoPLs on the monolayer trans, and of FAs in cis, with respect to the site of membrane fusion, result in the induction of exocytosis and inhibition of endocytosis? This is better understood on the basis of the molecular mechanism of membrane fusion, which envisages the existence of a stable lipid hemifusion intermediate which requires energy to proceed to pore formation [55–57]. The

membrane change induced by snake PLA₂s lowers this energy barrier and thus induces exocytosis and inhibits the reverse process of membrane fission, involved in endocytosis, for the very same reason [49, 53]. This rationale explains well the finding that crotoxin injected into the cytosol inhibited exocytosis [58], because this generates the opposite topological situation of LysoPLs on the cytosolic leaflet, which is anti-fusogenic.

The consequences of snake PLA₂ action are clearly different depending on the target membrane. At the motor endplate it causes the release of the ready-to-release pool of synaptic vesicles, and very likely also of the recycling pool of vesicles, and inhibits their retrieval [49, 59–61]. The PLA₂ myotoxins are expected to promote exocytosis and inhibit endocytosis at the sarcolemmal level, but no information about this possibility is yet available.

The second important consequence of the presence of LysoPLs and FAs within the membrane is that they increase its permeability to ions [62–66], leading to loss of membrane potential due to the re-equilibration of Na⁺, K⁺ and Cl⁻ ions [67]. If one considers that the highest transmembrane concentration gradient present at the plasma membrane is that of Ca²⁺, estimated to be of four orders of magnitude, from the millimolar outside to the 0.1 μM in the cytosol, it is not surprising that snake PLA₂ neurotoxins, as well as the simple addition of a LysoPL/FA equimolar mixture, cause a rapid increase of [Ca²⁺] within the nerve terminals [68] (Fig. 2, right panel). In principle, Ca²⁺ can enter directly through membrane lesions caused by LysoPLs/FAs and/or through voltage-gated Ca²⁺ channels, activated by membrane depolarization. The channels inhibited by ω-conotoxin MVIIC and nimodipine were reported to contribute little, if any, to this Ca²⁺ influx in primary cultures of neurons [68]. On the other hand, inhibitors of voltage-gated Ca²⁺ channels were found to substantially reduce the damage caused by β-bungarotoxin on the isolated rat phrenic nerve/diaphragm [54]. At variance, in the mouse hemidiaphragm, the paralysis time induced by different neurotoxins was not affected by the presence of specific inhibitors of the Ca²⁺ channels known to operate at the NMJ [68; Caccin et al, unpublished observations]. Whatever the exact mode of Ca²⁺ entry, this cytosolic [Ca²⁺] rise by itself causes the exocytosis of all the reserve pool of synaptic vesicles (Fig. 2), as was clearly documented by studies employing α-latrotoxin [61, 69, 70].

The PLA₂ activity of presynaptic snake neurotoxins is not FA specific. Eicosapentanoic acid and arachidonic acid were recently found to promote exocytosis as deduced from increased membrane capacitance in PC-12 cells [71]. Moreover, arachidonic acid, and

some detergents, were found to stimulate the release of Munc18 from syntaxin with ensuing formation of SNARE complexes, a passage which is expected to increase exocytosis [72, 73]. Moreover, omega-3 and omega-6 polyunsaturated FAs were found to stimulate membrane expansion at the nerve growth cone by a mechanism requiring syntaxin 3 [74]. Accordingly, it is possible that these FAs contribute to the increased neuroexocytosis stimulated by the snake neurotoxins, mentioned above. The possibility that the FAs generated by the snake PLA₂ toxins may partition into intracellular organelles should also be considered. FA are known uncouplers of mitochondrial respiration, with inhibition of ATP production [75], and their involvement in the action of snake PLA₂ neurotoxins was suggested long ago [76]. However, this is not supported experimentally, as FAs alone do not inhibit neurotransmitter release at the NMJ [49]. Moreover, the effect of the neurotoxins at the NMJ and on synaptosomes is rapidly reversed by albumin washing, which removes FAs [50, 67], and this should not be the case if FAs are inside mitochondria. Myotoxins were shown to induce the production of FAs in primary human myoblasts and mouse NB41A3 neuroblastoma cells [77, 78] and *in vivo* after myotoxin injection in muscle tissue [79]. LysoPLs were not measured at the same time. The ability of LysoPLs to induce membrane damage in muscle fibers has been described [80]. At the present time, it cannot be excluded that FAs could play a role in myotoxin intoxication of muscle cells, through uncoupling of mitochondria, since they are highly dependent on the activity of these organelles.

The Lys49 PLA₂ myotoxins are devoid of enzymatic activity [17, 46, 81], and therefore their membrane action has to be explained on grounds different from direct hydrolysis of phospholipids. These PLA₂ homologues have a highly cationic face [82–84]. Accordingly, they preferentially disrupt the integrity of negatively-charged liposomes [85, 86], and the addition of phosphatidylserine and phosphatidic acid to erythrocytes renders these otherwise resistant cells susceptible to the lytic effect of these toxins [42]. Thus, it is possible that negatively-charged microdomains in cell membranes constitute ‘acceptor’ sites for this group of basic myotoxins. The preferential cytotoxicity of Lys49 PLA₂s for differentiated muscle cells may depend on the appearance of protein receptors or anionic lipidic microdomains following the fusion of myoblasts to form myotubes and fully differentiated muscle fibers. The alternative explanation that myotubes are more susceptible to any type of membrane-perturbing agent has been discarded [34].

A large set of experimental evidence indicates that a cationic-hydrophobic stretch of residues present within the C-terminal region of the Lys49 myotoxins is responsible for membrane damage. Synthetic peptides corresponding to this region are cytotoxic in eukaryotes and prokaryotes [87–91], and the higher susceptibility of myotubes in comparison to myoblasts is also reproduced by such synthetic peptides [34]. The role of this molecular region in myotoxicity and liposome disruption is also supported by site-directed mutagenesis experiments [19, 46, 92]. Moreover, cytotoxicity and myotoxicity can be mimicked by the same C-terminal peptides made with D-amino acids, arguing against a specific protein-protein interaction [91]. This region is able to disorganize lipid bilayers owing to its cationic-hydrophobic property. The dimeric character of many Lys49 PLA₂s may contribute to their mechanism of action by allowing a change in quaternary structure that favours membrane contact and penetration [93, 94]. In addition, the dimeric character of these toxins may enhance their membrane-damaging effects by increasing binding affinity owing to the divalent interaction, as opposed to the monovalent binding of monomers; the latter ones are still capable of exerting myotoxicity and cytotoxicity, though with a lower potency than the dimers [22, 95]. An FA molecule bound to the inactive catalytic site has been observed in the crystal structure of some of these myotoxins, and proposed to induce the exposure of a 'hydrophobic knuckle' involving the side chains of hydrophobic residues that may contribute to bilayer disorganization [96]. This hypothesis might explain the strict conservation of the 'active site' in these enzymatically-inactive molecules [96]. It might also explain the puzzling observation that alkylation of the His48 of the 'catalytic centre' of Lys49 myotoxins reduces their toxicity [97, 98], as this chemical modification might interfere with the binding of the FA molecule, thus precluding the conformational change that exposes the hydrophobic knuckle.

The membrane perturbation induced by the Lys49 myotoxins increases the permeability of liposomes to entrapped probes, and of myotubes to Ca²⁺ [35, 86]. The entry of Ca²⁺ ions is very large and is compatible with the identification by scanning electron microscopy of large lesions of the sarcolemma [25, 37], as well as with the immediate (within 10–60 s) muscle fiber contractions observed intravitaly upon exposure to a Lys49 myotoxin [99]. A combined effect of both LysoPLs/FAs and toxin-induced membrane perturbation seems to be involved in the action of the catalytically-active Asp49 myotoxic PLA₂s because, in the absence of catalysis, there is a residual myotoxic effect [8, 85, 98]. This mixed type of membrane-

perturbing activity is also supported by experiments employing mutants of a Ser49 PLA₂ homologue in which enzymatic activity was restored by substituting three residues at the Ca²⁺-binding loop, in addition to the Ser49/Asp49 substitution [47]. Microscopic observations clearly indicate that membrane damage does not occur by osmotic lysis, but instead by a direct perturbation of membrane integrity leading to disorganization and disruption [99].

Muscle fiber plasma membrane damage, provoked either by catalytically-dependent or -independent mechanisms, triggers a rapid sequence of degenerative events that bring the muscle cells beyond the 'point of no return' within minutes. Ultrastructural and intravital observations document such rapid membrane damage with rapid depolarization of muscle fibers [37, 99–106]. This is accompanied by a prominent influx of Ca²⁺ [35, 79], which is the most significant consequence of plasma membrane disruption, since it promotes a complex series of cellular derangements (see below).

Injection of myotoxins in a muscle generates a concentration gradient of PLA₂s, from a high concentration spot at the injection site to lower concentrations in the neighbouring muscle regions. Such a gradient implies that the extent of damage to the sarcolemma might vary in different muscle fascicles. Some fibers close to the injection site would be drastically and irreversibly damaged, without any possibility of repair. However, in regions distant from the central injection area there might be muscle fibers suffering more limited membrane damage. It is suggested that some of these fibers might be able to repair such limited membrane perturbation, by a Ca²⁺-dependent repair mechanism that involves the fusion of membrane vesicles, with the participation of dysferlin, calpains and annexins [107]. Thus, the concept of thresholds of muscle damage, which depend on the extent of membrane perturbation, is an issue that needs to be investigated in PLA₂-induced myotoxicity.

The general conclusion that can be drawn at this point is that, whatever membrane perturbation is caused by the snake neurotoxins and myotoxins, the major event in cellular intoxication is the same: an increase of ion permeability with alteration of membrane potential, and what appears to be more important, a large increase in the cytosolic [Ca²⁺], predominantly due to an influx from the extracellular space.

Calcium entry and cellular degenerative events

Ca²⁺-mediated signalling is one of the major intracellular signalling mechanisms in all cells, and it is certainly a major regulator of nerve and muscle physiology [108, 109]. The large increase of cytosolic

[Ca²⁺] caused by the snake PLA₂ myotoxins and neurotoxins triggers in muscles and nerve terminals the physiological events controlled by Ca²⁺ signalling, but in an excessive, pathological way (Fig. 2). Nerve terminals release all their content of synaptic vesicles [61], whereas the myofilaments of skeletal muscle hypercontract, causing further mechanical damage to the sarcolemma [37, 99, 104]. As the increase of cytosolic [Ca²⁺] is persistent in time, these initial events are followed by a series of pathological consequences known to be linked to Ca²⁺ overload, leading muscle cells to a 'point of no return', *i.e.* irreversible damage and necrosis (Fig. 2).

Mitochondrial alteration is a common electron microscopy observation in animals injected with neurotoxins or myotoxins. Mitochondria are swollen with altered cristae, sometimes with internal vacuoles and disrupted membranes [104, 110–113] and may contain hydroxyapatite crystals in the matrix [102] as well as flocculent amorphous densities [104] (Fig. 2). In addition, *in vivo* observation of mitochondria in neurotoxin-treated neurons with membrane potential fluorescent indicators showed a progressive loss of membrane potential with parallel change of morphology from a spaghetti-like shape to an inactive rounded one [68]. Different factors may contribute to the mitochondrial impairment caused by snake PLA₂ toxins: a) the entry of Ca²⁺ in the cytosol activates the mitochondrial Ca²⁺ uniporter transport that leads to an accumulation of Ca²⁺ inside the mitochondrial matrix driven by the electrochemical potential; this eventually results in the precipitation of calcium phosphate and in mitochondrial damage. Clearly, the electrochemical energy used to pump Ca²⁺ inside goes at the detriment of the production of ATP. b) In the case of catalytically-active PLA₂ toxins, one should also consider that FAs are produced and that they very rapidly partition into intracellular organelles; they can thus act as mitochondrial uncouplers, particularly in muscles [75]. This latter effect would by itself cause a reduction of ATP production, which in turn contributes to the increase in cytosolic [Ca²⁺] because of inactivation of Ca²⁺-ATPase and of Ca²⁺ exchangers at the plasma membrane and endoplasmic/sarcoplasmic reticulum. c) An important consequence in muscles is that the damaged mitochondria release cell death mediators through the opening of the permeability transition pore [114]. This is suggested by the ability of cyclosporin A to abrogate myotoxicity induced by crotoxin [38] because cyclosporin A inhibits the opening of the permeability transition pore.

If Ca²⁺-induced mitochondrial alterations and loss of function are relatively simple to detect *in vivo*, this may not be the case for other less-prominent intracellular organelles. But it is very likely that they do

occur as well. The available knowledge of cellular biochemistry suggests that a variety of cytosolic hydrolases will be activated very rapidly by Ca²⁺. They include: a) Ca²⁺-dependent proteinases, such as calpains, which hydrolyze key structural components including desmin, titin and α -actinin, further compromising the mechanical integration of the contractile machinery in muscles [25, 115]; b) activation of intracellular Ca²⁺-dependent PLA₂s, which cause further hydrolysis of phospholipids in the plasma and intracellular membranes; and c) activation of other intracellular hydrolases. This will lead to a rapid degradation of several essential cell components, including the observed degeneration of neurofilaments at nerve terminals [54] and of the sarcomeres in muscle cells [25, 116, 117].

Cell necrosis and the release of contents from necrotic cells is accompanied by the onset of a prominent inflammatory reaction, with the synthesis and release of mediators that promote increments in vascular permeability leading to edema and recruitment of neutrophils and macrophages [104]. This opens the possibility that these inflammatory cells contribute to further tissue damage, although experiments made on the role of neutrophils in myonecrosis induced by a PLA₂ do not support this hypothesis [118]. However, the potential detrimental role of other inflammatory cells and mediators remains to be elucidated.

In addition to all these events, plasma membrane disruption may allow the entry of the PLA₂ toxins themselves, which are active in the Ca²⁺-enriched cytosol, causing further damage to intracellular membranes (Fig. 2). These proteins may enter because of their particular structural features or following the phospholipid hydrolysis and membrane perturbation they cause. There is evidence of toxins inside cells *in vitro* and *in vivo* [119–121]. Some PLA₂ toxins are known to affect mitochondria *in vitro* in Ca²⁺-containing media [72, 122, 123]. Nevertheless, it seems likely that such intracellular action is secondary to the primary disturbance to the integrity of plasma membrane.

The cellular and tissue consequences of these molecular pathogenic processes are clearly different in the case of neurotoxins and myotoxins, owing to the different anatomy of the targeted cells. In fact, the endplate of motoneurons is in most cases very distant from the cell body, which resides in the spinal cord (central nervous system) and is protected by the blood-brain barrier. Following the inactivation of the toxin, the damaged nerve terminal shrinks and is encircled by Schwann cells which phagocytose cell debris, while the innervated muscle becomes slightly atrophic [54, 124]. A very similar pattern of events takes place at the NMJ in latrotoxin-injected animals

[125]. This toxin is known to bind to the presynaptic membrane and to promote a large increase in cytosolic $[Ca^{2+}]$ [69, 70]. The strong similarities between the morphological alterations of nerve terminals induced by snake neurotoxins and latrotoxin [30, 37, 54, 112, 113, 125] strongly supports the role of Ca^{2+} overload in nerve terminal as the major degenerative event in the action of snake presynaptic PLA_2 neurotoxins.

At variance, the Ca^{2+} overload induced by myotoxic PLA_2 s in muscle fibers occurs throughout the length of these cells [35], causing widespread hypercontraction [104] and cell death through a variety of Ca^{2+} -dependent degenerative events [25]. In the case of the Lys49 PLA_2 myotoxins, the tissue degenerates around the site of toxin injection, whilst a systemic rhabdomyolysis develops with systemic toxins such as crotoxin and various elapid PLA_2 s [25, 84]. However, regardless of the local vs. systemic nature of the myotoxic effect, the mechanisms of cellular damage are similar for the two types of myotoxins.

Toxin inactivation, tissue repair and regeneration

Little is known about the processes involved in the inactivation of snake PLA_2 toxins *in vivo*, though it appears that they have to be inactivated before any repair/regeneration process can develop. There appears to be little doubt that toxins are eventually degraded and eliminated, but the kinetics and exact mechanisms of inactivation are ill-known. This knowledge should be particularly important as it may have therapeutic relevance. Ammodytoxin A has been shown to resist the reducing effect of glutathione [121]. PLA_2 -binding proteins, such as the M-type receptor described in skeletal muscle [126], may contribute to toxin sequestration and inhibition, since a recombinant soluble form of this receptor inhibits the enzymatic activity of PLA_2 s [127]. An interesting, albeit speculative, possibility for an inactivating mechanism occurring *in vivo* relates to the observation that myotoxic PLA_2 s can induce the degranulation of mast cells, with the consequent release of their mediators [128, 129]. Among these, heparin could play an important inactivating role as myotoxic PLA_2 are highly basic proteins, and heparin inhibits the myotoxic effect of many PLA_2 s [130, 131]. Thus heparin, if rapidly released by mast cells upon exposure to PLA_2 myotoxins, may constitute a host protective factor that would limit the spread of myonecrosis. This possibility would need to be evaluated experimentally. Likewise, anionic domains abundant in extracellular matrix glycosaminoglycans may inhibit cationic myotoxins. A protective role of mast cell-derived mediators during bee (*Apis mellifera*) and snake (*Atractaspis engaddensis*) venom poisoning was shown in a mouse model [132]. Other

possible mechanisms, such as proteolytic degradation, denaturation by reducing agents or complex formation with plasma components known to inhibit PLA_2 s [133], await to be investigated.

Within a few days/weeks, the nerve terminal, damaged by the snake PLA_2 presynaptic neurotoxins, regenerates, and the innervated muscle reacquire their structure, size and functional activity [134]. Presynaptic Schwann cells appear to play a major role in NMJ regeneration after nerve terminal crushing [135], and it is likely that they also play an important role in the case of neurotoxin-induced damage. In the case of PLA_2 -induced myotoxicity, an orderly and successful regeneration of muscle fibers occurs [134]. This proceeds by a stereotyped sequence of events characterized by phagocytosis and removal of necrotic material, followed by activation of myogenic satellite cells, which are present in the periphery of muscle fibers and are resistant to the action of these toxins [134]. Upon their activation to myoblasts, there is a replicative phase, followed by the fusion of myoblasts to form myotubes, with the appearance of a number of proteins characteristic of differentiated muscle fibers, and then the development of mature fibers which conserve centrally-located nuclei, a characteristic feature of regenerating muscle [134, 136]. Myotoxic PLA_2 s such as notexin have become highly useful tools to investigate the cellular mechanisms involved in muscle regeneration [134]. When muscles are injected with crude viperid venoms, which contain hemorrhagic metalloproteinases and other toxic proteins in addition to myotoxic PLA_2 s, a poor regenerative response has been described [137]. This is likely to depend on the effects exerted by venom components to the microvasculature, jeopardizing blood supply to regenerating tissue. Moreover, damage to peripheral nerve terminals and incomplete removal of necrotic debris after injection of crude venoms are also likely to contribute to poor regeneration [136, 137]. Thus, PLA_2 myotoxins and neurotoxins are relevant tools not only to investigate the cellular mechanisms of nerve and muscle degeneration, but also the processes associated with repair and regeneration.

Conclusions and future lines of investigation

Hundreds of species of venomous snakes, classified in the families Elapidae and Viperidae, have evolved a very large variety of PLA_2 toxins with an amazing diversification in their toxic profiles, some of them even lacking PLA_2 activity. These toxins display different modes of binding to cells and different mechanisms of plasma membrane damage. As it

emerges from the present discussion, the initial phases of the intoxication process are ill-known for several groups of toxins, and this clearly calls for further investigations. The identification of the receptors of PLA₂s in nerve and muscle is a subject that demands attention. Besides the relevance for a better understanding of their basic mechanism of action, such knowledge is also important considering the major human health impact that snakebite envenomings cause around the world [12].

Whatever the basis for cell specificity of toxic PLA₂s, it clearly emerges that the different initial molecular pathogenic processes converge into a major event which plays the central role: the entry of Ca²⁺, mainly from the extracellular medium, into the cell cytosol. The initial consequences of increased cytosolic [Ca²⁺] are different in nerve terminals and muscle cells, as synaptic vesicle fusion and insertion in nerve terminal plasmalemma takes place in the former cells, whereas hypercontraction of sarcomeres occurs in the latter. However, many accompanying and ensuing events are common for the two cell types. Mitochondria collapse following an overwhelming calcium uptake, and possibly due to FA uncoupling, with progressive loss of ATP, which is essential for pumping Ca²⁺ out of the cell and for repair reactions. Ca²⁺ activates a variety of hydrolytic enzymes which contribute to degeneration of nerve terminals and muscle necrosis, depending on the toxicological profile of each toxin.

On the basis of the present discussion, we would like to propose to focus research efforts on increased cytosolic [Ca²⁺] as the central pathogenic event, which triggers a cascade of cellular degenerative processes (Fig. 2). Several techniques are available to image intracellular calcium in a time- and space-resolved manner, and their use will undoubtedly contribute to further insights in the pathogenic events induced by the snake PLA₂ toxins in nerve terminals and muscle cells. On these grounds, the potential role of the various components of the Ca²⁺-signalling kit in modulating such an increment in Ca²⁺ in the cytosol also deserves further investigation.

Acknowledgements. Work in the authors' laboratories is supported by Vicerrectoría de Investigación, Universidad de Costa Rica, and by research grants from Telethon-Italia GP0272Y01, the University of Padova and FIRBRBNE01RHZM.

- 1 Kini, R. M. (1997) Venom Phospholipase A₂ Enzymes. John Wiley & Sons, Chichester.
- 2 Harris, J.B. (1997) Toxic phospholipases in snake venom: an introductory review. Symp. Zool. Soc. Lond. 70, 235–250.
- 3 Connolly, S., Trevett, A. J., Nwokolo, N. C., Lalloo, D. G., Naraq, S., Mantle, D., Schofield, I. S., Fawcett, P. R., Harris, J. B. and Warrell, D. A. (1995) Neuromuscular effects of papuan taipan snake venom. Ann. Neurol. 38, 916–920.
- 4 Prasarnpun, S., Walsh, J., Awad, S. S. and Harris, J. B. (2005) Envenoming bites by kraits: the biological basis of treatment-resistant neuromuscular paralysis. Brain 128, 2987–2996.
- 5 Rosenberg (1997) Lethal potency of phospholipase A₂ enzymes. In: Kini, K. (Ed.), Venom Phospholipase A₂ Enzymes. Structure, Function and Mechanism. John Wiley & Sons, Chichester, p. 129–154.
- 6 Warrell, D. A. (1995) Clinical toxicology of snakebite in Africa and the Middle East/Arabian Peninsula. In: Meier, J. and White, J. (Eds.), Handbook of Clinical Toxicology of Animal Venoms and Poisons. CRC Press, Florida, p. 433–492.
- 7 Lomonte, B., Angulo, Y., Rufini, S., Cho, W., Giglio, J. R., Ohno, M., Daniele, J. J., Geoghegan, P. and Gutiérrez, J. M. (1999) Comparative study of the cytolytic activity of myotoxic phospholipases A₂ on mouse endothelial (tEnd) and skeletal muscle (C2C12) cells *in vitro*. Toxicol 37, 145–158.
- 8 Bultrón, E., Thelestam, M. and Gutiérrez, J. M. (1993) Effects on cultured mammalian cells of myotoxin III, a phospholipase A₂ isolated from *Bothrops asper* (terciopelo) venom. Biochim. Biophys. Acta 1179, 253–259.
- 9 Lomonte, B., Tarkowski, A. and Hanson, L. Å. (1994) Broad cytolytic specificity of myotoxin II, a lysine-49 phospholipase A₂ of *Bothrops asper* snake venom. Toxicol 32, 1359–1369.
- 10 Teixeira, C. F. P., Landucci, E. C. T., Antunes, E., Chacur, M. and Cury, Y. (2003) Inflammatory effects of snake venom myotoxic phospholipases A₂. Toxicol 42, 947–962.
- 11 Saravia-Otten, P., Gutiérrez, J. M., Arvidson, S., Thelestam, M. and Flock, J.-I. (2007) Increased infectivity of *Staphylococcus aureus* in an experimental model of snake venom-induced tissue damage. J. Infect. Dis. 196, 748–754.
- 12 Gutiérrez, J. M., Theakston, R. D. G. and Warrell, D. A. (2006) Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Medicine 3, e 150.
- 13 Rappuoli, R. and Montecucco, C. (Editors) (1997) Protein Toxins and their Use in Cell Biology. Oxford University Press, Oxford.
- 14 Gutiérrez, J. M., Editor (2003) Special Issue: Myotoxic phospholipases. Toxicol 42, 825–986.
- 15 Pungercar J. and Krizaj, I. (2007) Understanding the molecular mechanism underlying the presynaptic toxicity of secreted phospholipases A₂. Toxicol 50, 871–92.
- 16 Rossetto, O. and Montecucco, C. (2007) Presynaptic neurotoxins with enzymatic activities. Handb. Exp. Pharmacol. 184, 129–170.
- 17 Scott, D. (1997) Phospholipase A₂: structure and catalytic properties. In: Kini R (ed) Venom phospholipase A₂ enzymes: structure, function and mechanism. John Wiley & Sons, Chichester, p 97–128.
- 18 Lomonte, B., Angulo, Y. and Calderón, L. (2003) An overview of Lysine-49 phospholipase A₂ myotoxins from crotalid snake venoms and their structural determinants of myotoxic action. Toxicol 42, 885–901.
- 19 Chioato, L. and Ward, R. J. (2003) Mapping structural determinants of biological activities in snake venom phospholipases A₂ by sequence analysis and site directed mutagenesis. Toxicol 42, 869–883.
- 20 Kwong, P. D., McDonald, N. Q., Sigler, P. B. and Hendrickson, W. A. (1995) Structure of beta 2-bungarotoxin: potassium channel binding by Kunitz modules and targeted phospholipase action. Structure 3, 1109–1119.
- 21 Bon, C. (1997) Multicomponent neurotoxic phospholipases A₂ In: Kini, R. (Ed) Venom phospholipase A₂ enzymes: structure, function and mechanism. John Wiley & Sons, Chichester, p 269–285.
- 22 Montecucco, C. and Rossetto, O. (2008) On the quaternary structure of taipoxin and textilotoxin: the advantage of being multiple. Toxicol, in press
- 23 Milani, R., Jorge, M. T., Ferraz de Campos, F. P., Martins, F. P., Bousso, A., Cardoso, J. L. C., Ribeiro, L. A., Fan, H. W., Franca, F. O. S., Sano-Martins, I. S., Cardoso, D., Fernández, I. C. O. F., Fernandes, J. C., Aldred, V. L., Sandoval, M. P.,

- Puerto, G., Theakston, R. D. G. and Warrell, D. A., 1997. Snake bites by the jararacucu (*Bothrops jararacussu*): clinicopathological studies of 29 proven cases in Sao Paulo state, Brazil. *Q. J. Med.* 90, 323–334.
- 24 Warrell, D. A. (2004) Snakebites in Central and South America: Epidemiology, clinical features and clinical management. In: Campbell, J. A., Lamar, W. W. (Eds.), *The Venomous Reptiles of the Western Hemisphere*, Vol II. Ithaca: Comstock, p. 709–761.
 - 25 Gutiérrez, J. M. and Ownby, C. L. (2003) Skeletal muscle degeneration induced by venom phospholipases A₂: insights into the mechanisms of local and systemic myotoxicity. *Toxicon* 42, 915–31.
 - 26 Salvini, T. F., Amaral, A. C., Miyabara, E. H., Turri, J. A. O., Danella, P. M. and Selistre-de-Araújo, H. S. (2001) Systemic skeletal muscle necrosis induced by crotoxin. *Toxicon* 39, 1141–1149.
 - 27 Ponraj, D. and Gopalakrishnakone, P. (1996) Establishment of an animal model for myoglobinuria by use of a myotoxin from *Pseudechis australis* (king brown snake) venom in mice. *Lab. Anim. Sci.* 46, 393–398.
 - 28 Rowan, E. G. (2001) What does beta-bungarotoxin do at the neuromuscular junction? *Toxicon* 39, 107–118.
 - 29 Lambeau, G. and Lazdunski, M. (1999) Receptors for a growing family of secreted phospholipases A₂. *Trends Pharmacol. Sci.* 20, 162–70.
 - 30 Abe, T., Limbrick, A. R. and Miledi, R. (1976) Acute muscle denervation induced by beta-bungarotoxin. *Proc. R. Soc. Lond. B Biol. Sci.* 194, 545–553.
 - 31 Rehm, H. and Betz, H. (1982) Binding of beta-bungarotoxin to synaptic membrane fractions of chick brain. *J. Biol. Chem.* 257, 10015–10022.
 - 32 Lambeau, G., Barhanin, J., Schweitz, H., Qar, J. and Lazdunski, M. (1989) Identification and properties of very high affinity brain membrane-binding sites for a neurotoxic phospholipase from the taipan venom. *J. Biol. Chem.* 264, 11503–11510.
 - 33 Othman, I. B., Spokes, J. W. and Dolly, J. O. (1982) Preparation of neurotoxic ³H-beta-bungarotoxin: demonstration of saturable binding to brain synapses and its inhibition by toxin I. *Eur. J. Biochem.* 128, 267–276.
 - 34 Angulo, Y. and Lomonte, B. (2005) Differential susceptibility of C2C12 myoblasts and myotubes to group II phospholipase A₂ myotoxins from crotalid snake venoms. *Cell Biochem. Funct.* 23, 307–313.
 - 35 Villalobos, J. C., Mora, R., Lomonte, B., Gutiérrez, J. M. and Angulo, Y. (2007) Cytotoxicity induced in myotubes by a Lys49 phospholipase A₂ homologue from the venom of the snake *Bothrops asper*: Evidence of rapid plasma membrane damage and a dual role for extracellular calcium. *Toxicol. In Vitro* 21, 1382–1389.
 - 36 Harris, J. B., Johnson, M. A. and Karlsson, E. (1975) Pathological responses of rat skeletal muscle to a single subcutaneous injection of a toxin isolated from the venom of the Australian tiger snake, *Notechis scutatus scutatus*. *Clin. Exp. Pharmacol. Physiol.* 2, 383–404.
 - 37 Dixon, R. W. and Harris, J. B. (1996) Myotoxic activity of the toxic phospholipase, notexin, from the venom of the Australian tiger snake. *J. Neuropathol. Exp. Neurol.* 55, 1230–1237.
 - 38 Miyabara, E. H., Baptista, I. L., Lomonte, B., Selistre-de-Araújo, H. S., Gutiérrez, J. M. and Moriscot, A. S. (2006) Effect of calcineurin inhibitors on myotoxic activity of crotoxin and *Bothrops asper* phospholipase A₂ myotoxins *in vivo* and *in vitro*. *Comp. Biochem. Physiol. C* 143, 284–294.
 - 39 Rouault, M., Rash, L., Escoubas, P., Boilard, E., Bollinger, J., Lomonte, B., Maurin, T., Guillaume, C., Canaan, S., Deregnacourt, C., Schrével, J., Doglio, A., Gutiérrez, J. M., Lazdunski, M., Gelb, M. H. and Lambeau, G. (2006) Neurotoxicity and other pharmacological activities of the snake venom phospholipase A₂ OS2: The N-terminal region is more important than enzymatic activity. *Biochemistry* 45, 5800–5816.
 - 40 Yamazaki, Y., Matsunaga, Y., Nakano Y. and Morita, T. (2005) Identification of vascular endothelial growth factor receptor-binding protein in the venom of Eastern cottonmouth: a new role of snake venom myotoxic Lys49-phospholipase A₂. *J. Biol. Chem.* 280, 29989–29992.
 - 41 Fujisawa, D., Yamazaki, Y., Lomonte, B. and Morita, T. (2008) Catalytically inactive phospholipase A₂ homologue binds to vascular endothelial growth factor receptor-2 via C-terminal loop region. *Biochem. J.* 411, 515–522.
 - 42 Díaz, C., León, G., Rucavado, A., Rojas, N., Schroit, A. J. and Gutiérrez, J. M. (2001) Modulation of the susceptibility of human erythrocytes to snake venom myotoxic phospholipases A₂: role of negatively-charged phospholipids as potential membrane binding sites. *Arch. Biochem. Biophys.* 391, 56–64.
 - 43 Barchan, D., Kachalsky, S., Neumann, D., Vogel, Z., Ovadia, M., Kochva, E. and Fuchs, S. (1992) How the mongoose can fight the snake: the binding site of the mongoose acetylcholine receptor. *Proc. Natl. Acad. Sci. USA* 89, 7717–7721.
 - 44 Takacs, Z., Wilhelmsen, K. C. and Sorota, S. (2001) Snake alpha-neurotoxin binding site on the Egyptian cobra (*Naja haje*) nicotinic acetylcholine receptor is conserved. *Mol. Biol. Evol.* 18, 1800–1809.
 - 45 Tsai, I. H. and Wang, Y. M. (1998) Effect of site directed mutagenesis on the activity of recombinant trimucrotoxin, a neurotoxic phospholipase from *Trimeresurus mucrosquamatus* venom. *Toxicon* 36, 1591–1597.
 - 46 Chioato, L., Aragão, E. A., Lopes Ferreira, T., Ivo de Medeiros, A., Faccioli, L. H. and Ward, R. J. (2007) Mapping of the structural determinants of artificial and biological membrane damaging activities of a Lys49 phospholipase A₂ by scanning alanine mutagenesis. *Biochim. Biophys. Acta* 1768, 1247–1257.
 - 47 Petan, T., Krizaj, I. and Pungercar, J. (2007) Restoration of enzymatic activity in a Ser-49 phospholipase A₂ homologue decreases its Ca²⁺-independent membrane-damaging activity and increases its toxicity. *Biochemistry* 46, 12795–12809.
 - 48 Ivanovski, G., Petan, T., Krizaj, I., Gelb, M. H., Gubenšek, F. and Pungercar, J. (2004) Basic amino acid residues in the beta-structure region contribute, but not critically, to presynaptic neurotoxicity of ammodytoxin A. *Biochim. Biophys. Acta* 1702, 217–225.
 - 49 Rigoni, M., Caccin, P., Gschmeissner, S., Koster, G., Postle, A. D., Rossetto, O., Schiavo, G. and Montecucco, C. (2005) Equivalent effects of snake PLA₂ neurotoxins and lysophospholipid-fatty acid mixtures. *Science* 310, 1678–1680.
 - 50 Caccin, P., Rigoni, M., Bisceglie, A., Rossetto, O. and Montecucco, C. (2006) Reversible skeletal neuromuscular paralysis induced by different lysophospholipids. *FEBS Lett.* 580, 6317–6321.
 - 51 Megighian, A., Rigoni, M., Caccin, P., Zordan, M. A. and Montecucco, C. (2007) A lysolecithin/fatty acid mixture promotes and then blocks neurotransmitter release at the *Drosophila melanogaster* larval neuromuscular junction. *Neurosci. Lett.* 416, 6–11.
 - 52 Kini, R. M. (2003) Excitement ahead: structure, function and mechanism of snake venom phospholipase A₂ enzymes. *Toxicon* 42, 827–840.
 - 53 Rossetto, O., Morbiato, L., Caccin, P., Rigoni, M. and Montecucco, C. (2006) Presynaptic enzymatic neurotoxins. *J. Neurochem.* 97, 1534–1545.
 - 54 Prasarnpun, S., Walsh, J. and Harris, J. B. (2004) Beta-bungarotoxin-induced depletion of synaptic vesicles at the mammalian neuromuscular junction. *Neuropharmacology* 47, 304–314.
 - 55 Chernomordik, L. V., Leikina, E., Frolov, V., Bronk, P. and Zimmerberg, J. (1997) An early stage of membrane fusion mediated by the low pH conformation of influenza hemagglutinin depends upon membrane lipids. *J. Cell Biol.* 136, 81–93.

- 56 Chernomordik, L. V. and Kozlov, M. M. (2003) Protein-lipid interplay in fusion and fission of biological membranes. *Annu. Rev. Biochem.* 72, 175–207.
- 57 Chernomordik, L. V., Zimmerberg, J. and Kozlov, M. M. (2006) Membranes of the world unite! *J. Cell Biol.* 175, 201–207.
- 58 Wei, S., Ong, W. Y., Thwin, M. M., Fong, C. W., Farooqui, A. A., Gopalakrishnakone, P. and Hong, W. (2003) Group IIA secretory phospholipase A₂ stimulates exocytosis and neurotransmitter release in pheochromocytoma-12 cells and cultured rat hippocampal neurons. *Neuroscience* 121, 891–898.
- 59 Rigoni, M., Schiavo, G., Weston, A. E., Caccin, P., Allegrini, F., Pennuto, M., Valtorta, F., Montecucco, C. and Rossetto, O. (2004) Snake presynaptic neurotoxins with phospholipase A₂ activity induce punctate swellings of neurites and exocytosis of synaptic vesicles. *J. Cell Sci.* 117, 3561–3570.
- 60 Bonanomi, D., Pennuto, M., Rigoni, M., Rossetto, O. and Montecucco, C. (2005) Taipoxin induces synaptic vesicle exocytosis and disrupts the interaction of synaptophysin I with VAMP2. *Mol. Pharmacol.* 67, 1901–1908.
- 61 Rizzoli, S. O. and Betz, W. J. (2005) Synaptic vesicle pools. *Nat. Rev. Neurosci.* 6, 57–69.
- 62 Sedlis, S. P., Corr, P. B., Sobel, B. E., and Ahumada, G. G. (1983) Lysophosphatidyl choline potentiates Ca²⁺ accumulation in rat cardiac myocytes. *Am J Physiol.* 244:H32–8.
- 63 Woodley, S. L., Ikenouchi, H. and Barry, W. H. (1991) Lysophosphatidylcholine increases cytosolic calcium in ventricular myocytes by direct action on the sarcolemma. *J. Mol. Cell. Cardiol.* 23, 671–680.
- 64 Leung, Y. M., Xion, Y., Ou, Y. J. and Kwan, C. Y. (1998) Perturbation by lysophosphatidylcholine of membrane permeability in cultured vascular smooth muscle and endothelial cells. *Life Sci.* 63, 965–973.
- 65 Wilson-Ashworth, H. A., Judd, A. M., Law, R. M., Freestone, B. D., Taylor, S., Mizukawa, M. K., Cromar, K. R., Sudweeks, S. and Bell, J. D. (2004) Formation of transient non-protein calcium pores by lysophospholipids in S49 lymphoma cells. *J. Membr. Biol.* 200, 25–33.
- 66 Li, X. H., Long, D. X., Li, W. and Wu, Y. J. (2007) Different mechanisms of lysophosphatidylcholine-induced Ca²⁺ mobilization in N2a mouse and SH-SY5Y human neuroblastoma cells. *Neurosci. Lett.* 424, 22–26.
- 67 Rugolo, M., Dolly, J. O. and Nicholls, D. G. (1986) The mechanism of action of beta-bungarotoxin at the presynaptic plasma membrane. *Biochem. J.* 233, 519–523.
- 68 Rigoni, M., Pizzo, P., Schiavo, G., Weston, A. E., Zatti, G., Caccin, P., Rossetto, O., Pozzan, T. and Montecucco, C. (2007) Calcium influx and mitochondrial alterations at synapses exposed to snake neurotoxins or their phospholipid hydrolysis products. *J. Biol. Chem.* 282, 11238–11245.
- 69 Ceccarelli, B. and Hurlbut, W. P. (1980) Ca²⁺-dependent recycling of synaptic vesicles at the frog neuromuscular junction. *J. Cell Biol.* 87, 297–303.
- 70 Ushkaryov, Y. A., Volynski, K. E. and Ashton, A. C. (2004) The multiple actions of black widow spider toxins and their selective use in neurosecretion studies. *Toxicon* 43, 527–542.
- 71 Ong, W. L., Jiang, B., Tang, N., Ling, S. F., Yeo, J. F., Wei, S., Farooqui, A. A. and Ong W. Y. (2006) Differential effects of polyunsaturated fatty acids on membrane capacitance and exocytosis in rat pheochromocytoma-12 cells. *Neurochem. Res.* 31, 41–48.
- 72 Rickman C, Davletov B (2005) Arachidonic acid allows SNARE complex formation in the presence of Munc18. *Chem. Biol.* 12, 545–553.
- 73 Latham CF, Osborne SL, Cryle MJ, Meunier FA. (2007) Arachidonic acid potentiates exocytosis and allows neuronal SNARE complex to interact with Munc18a. *J Neurochem.* 100, 1543–1554.
- 74 Darios F, Davletov B (2006) Omega-3 and omega-6 fatty acids stimulate cell membrane expansion by acting on syntaxin 3. *Nature* 440, 813–817.
- 75 Bernardi, P., Penzo, D. and Wojtczak, L. (2002) Mitochondrial energy dissipation by fatty acids. Mechanisms and implications for cell death. *Vitam. Horm.* 65, 97–126.
- 76 Wernicke, J. F., Vanker, A. D. and Howard, B. D. (1975) The mechanism of action of beta-bungarotoxin. *J. Neurochem.* 25, 483–496.
- 77 Fletcher, J. E., Hubert, M., Wieland, S. J., Gong, Q. H. and Jiang, M. S. (1996) Similarities and differences in mechanisms of cardiotoxins, melittin and other myotoxins. *Toxicon* 34, 1301–1311.
- 78 Soares, A. M., Oshima-Franco, Y., Vieira, C. A., Leite, G. B., Fletcher, J. E., Jiang, M. S., Cintra, A. C., Giglio, J. R. and Rodrigues-Simioni, L. (2002) Mn²⁺ ions reduce the enzymatic and pharmacological activities of bothropstoxin-I, a myotoxic Lys49 phospholipase A₂ homologue from *Bothrops jararacussu* snake venom. *Int. J. Biochem. Cell Biol.* 34, 668–677.
- 79 Gutiérrez, J. M., Ownby, C. L. and Odell, G. V. (1984) Isolation of a myotoxin from *Bothrops asper* venom: partial characterization and action on skeletal muscle. *Toxicon* 22, 115–128.
- 80 Pestronk, A., Parhad, I. M., Drachman, D. B. and Price, D. L. (1982) Membrane myopathy: morphological similarities to Duchenne muscular dystrophy. *Muscle Nerve* 5, 209–214.
- 81 Ward, R. J., Chioato, L., de Oliveira, A. H. C., Ruller, R. and Sá, J. M. (2002) Active-site mutagenesis of a Lys49-phospholipase A₂: biological and membrane-disrupting activities in the absence of catalysis. *Biochem. J.* 362, 89–96.
- 82 Falconi, M., Desideri, A. and Rufini, S. (2000) Membrane-perturbing activity of Viperidae myotoxins: an electrostatic surface potential approach to a puzzling problem. *J. Molec. Recogn.* 13, 14–19.
- 83 Murakami, M. and Arni, R. K. (2003) A structure based model for liposome disruption and the role of catalytic activity in myotoxic phospholipase A₂s. *Toxicon* 42, 903–913.
- 84 Gutiérrez, J. M., Ponce-Soto, L. A., Marangoni, S. and Lomonte, B. (2008) Systemic and local myotoxicity induced by snake venom group II phospholipases A₂: comparison between crotoxin and a Lys49 PLA₂ homologue. *Toxicon* 51, 80–92.
- 85 Díaz, C., Gutiérrez, J. M., Lomonte, B. and Gené, J. A. (1991) The effect of myotoxins isolated from *Bothrops* snake venoms on multilamellar liposomes: relationship to phospholipase A₂, anticoagulant and myotoxic activities. *Biochim. Biophys. Acta* 1070, 455–460.
- 86 Rufini, S., Cesaroni, P., Desideri, A., Farias, R., Gubensek, F., Gutiérrez, J. M., Luly, P., Massoud, R., Morero, R. and Pedersen, J. Z. (1992) Calcium ion independent membrane leakage induced by phospholipase-like myotoxins. *Biochemistry* 31, 12424–12430.
- 87 Lomonte, B., Moreno, E., Tarkowski, A., Hanson, L. Å. and Maccarana, M. (1994) Neutralizing interaction between heparins and myotoxin II, a Lys-49 phospholipase A₂ from *Bothrops asper* snake venom. Identification of a heparin-binding and cytolytic toxin region by the use of synthetic peptides and molecular modeling. *J. Biol. Chem.* 269, 29867–29873.
- 88 Lomonte, B., Pizarro-Cerdá, J., Angulo, Y., Gorvel, J. P. and Moreno, E. (1999) Tyr-Trp-substituted peptide 115–129 of a Lys49 phospholipase A₂ expresses enhanced membrane-damaging activities and reproduces its *in vivo* myotoxic effect. *Biochim. Biophys. Acta* 1461, 19–26.
- 89 Páramo, L., Lomonte, B., Pizarro-Cerdá, J., Bengoechea, J. A., Gorvel, J. P. and Moreno, E. (1998) Bactericidal activity of Lys49 and Asp49 myotoxic phospholipases A₂ from *Bothrops asper* snake venom: synthetic Lys49 myotoxin II-(115–129)-peptide identifies its bactericidal region. *Eur. J. Biochem.* 253, 452–461.
- 90 Núñez, C. E., Angulo, Y. and Lomonte, B. (2001) Identification of the myotoxic site of the Lys49 phospholipase A₂ from *Agkistrodon piscivorus piscivorus* snake venom: synthetic C-terminal peptides from Lys49, but not from Asp49 myotoxins, exert membrane-damaging activities. *Toxicon* 39, 1587–1594.

- 91 Lomonte, B., Angulo, Y. and Santamaría, C. (2003) Comparative study of synthetic peptides corresponding to region 115–129 in Lys49 myotoxic phospholipases A₂ from snake venoms. *Toxicon* 42, 307–312.
- 92 Chioato, L., de Oliveira, A. H. C., Ruller, R., Sá, J. M. and Ward, R. J. (2002) Distinct sites for myotoxic and membrane-damaging activities in the C-terminal region of a Lys49-phospholipase A₂. *Biochem. J.* 366, 971–976.
- 93 da Silva Giotto, M. T., Garrat, R. C., Oliva, G., Mascarenhas, Y. P., Giglio, J. R., Cintra, A. C. O., de Azevedo Jr., W. F., Arni, R. K. and Ward, R. J. (1998) Crystallographic and spectroscopic characterization of a molecular hinge: conformational changes in bothropstoxin I, a dimeric Lys49 phospholipase A₂ homologue. *Prot. Struct. Funct. Genet.* 30, 442–454.
- 94 Magro, A. J., Soares, A. M., Giglio, J. R. and Fontes, M. R. M. (2003) Crystal structures of BnSP-7 and BnSP-6, two Lys49-phospholipases A₂: quaternary structure and inhibition mechanism insights. *Biochem. Biophys. Res. Comm.* 311, 713–720.
- 95 Angulo, Y., Gutiérrez, J. M., Soares, A. M., Cho, W. and Lomonte B (2005) Myotoxic and cytolytic activities of dimeric Lys49 phospholipase A₂ homologues are reduced, but not abolished, by a pH-induced dissociation. *Toxicon* 46, 291–296.
- 96 Ambrosio, A. L. B., Nonato, M. C., Selistre de Araujo, H. S., Arni, R. K., Ward, R. J., Ownby, C. L., de Souza, D. H. F. and Garrat, R. C. (2005) A molecular mechanism for Lys49-phospholipase A₂ activity based on ligand-induced conformational change. *J. Biol. Chem.* 280, 7326–7335.
- 97 Díaz, C., Gutiérrez, J. M., Lomonte, B. and Núñez, J. (1993) *p*-Bromophenacyl bromide modification of *Bothrops asper* myotoxin II, a lysine-49 phospholipase A₂, affects its pharmacological activities. *Toxicon* 31, 1202–1206.
- 98 Soares, A. M., Andriao-Escarso, S. H., Bortoleto, R. K., Rodrigues-Simioni, L., Arni, R. K., Ward, R. J., Gutiérrez, J. M. and Giglio, J. R. (2001) Dissociation of enzymatic and pharmacological properties of piratoxins-I and -III, two myotoxic phospholipases A₂ from *Bothrops pirajai* snake venom. *Arch. Biochem. Biophys.* 387, 188–196.
- 99 Lomonte, B., Lundgren, J., Johansson, B. and Bagge, U. (1994) The dynamics of local tissue damage induced by *Bothrops asper* snake venom and myotoxin II on the mouse cremaster muscle: an intravital and electron microscopic study. *Toxicon* 32, 41–55.
- 100 Díaz-Oreiro, C. and Gutiérrez, J. M. (1997) Chemical modification of histidine and lysine residues of myotoxic phospholipases A₂ isolated from *Bothrops asper* and *Bothrops godmani* snake venoms: effects on enzymatic and pharmacological properties. *Toxicon* 35, 241–252.
- 101 Bultrón, E., Gutiérrez, J. M. and Thelestam, M. (1993) Effects of *Bothrops asper* (terciopelo) myotoxin III, a basic phospholipase A₂, on liposomes and mouse gastrocnemius muscle. *Toxicon* 31, 217–222.
- 102 Gopalakrishnakone, P., Dempster, D. W., Hawgood, B. J. and Elder, H. Y. (1984) Cellular and mitochondrial changes induced in the structure of murine skeletal muscle by crotoxin, a neurotoxic phospholipase A₂ complex. *Toxicon* 22, 85–98.
- 103 Harris, J. B. and Maltin, C. A. (1982) Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, *Oxyuranus scutellatus*. *Br. J. Pharmacol.* 76, 61–75.
- 104 Gutiérrez, J. M., Ownby, C. L. and Odell, G. V. (1984) Pathogenesis of myonecrosis induced by crude venom and a myotoxin of *Bothrops asper*. *Exp. Mol. Pathol.* 40, 367–379.
- 105 Heluany, N. F., Homs-Brandeburgo, M. I., Giglio, J. R., Prado-Franceschi, J. and Rodrigues-Simioni, L. (1992) Effects induced by bothropstoxin, a component from *Bothrops jararacussu* snake venom, on mouse and chick muscle preparations. *Toxicon* 30, 1203–1210.
- 106 Melo, P. A., Burns, C. F., Blankemeyer, J. T. and Ownby, C. L. (2004) Membrane depolarization is the initial action of crotoxin on isolated murine skeletal muscle. *Toxicon* 43, 111–119.
- 107 Han, R. and Campbell, K. P. (2007) Dysferlin and muscle membrane repair. *Curr. Opin. Cell Biol.* 19, 409–416.
- 108 Rizzuto, R. and Pozzan, T. (2006) Microdomains of intracellular Ca²⁺: molecular determinants and functional consequences. *Physiol. Rev.* 86, 369–408.
- 109 Clapham, D. E. (2007) Calcium signalling. *Cell* 131, 1047–1058.
- 110 Harris, J. B. and Cullen, M. J. (1990) Muscle necrosis caused by snake venoms and toxins. *Electron Microsc. Rev.* 3, 183–211.
- 111 Chen, I. L. and Lee, C. Y. (1970) Ultrastructural changes in the motor nerve terminals caused by beta-bungarotoxin. *Virchows Arch. B Cell Pathol.* 6, 318–325.
- 112 Cull-Candy, S. G., Fohlman, J., Gustavsson, D., Lullmann-Rauch, R. and Thesleff, S. (1976) The effect of taipoxin and notexin on the function and fine structure of the murine neuromuscular junction. *Neuroscience* 1, 175–180.
- 113 Dixon, R. W. and Harris, J. B. (1999) Nerve terminal damage by β-bungarotoxin: its clinical significance. *Am. J. Pathol.* 154, 447–455.
- 114 Bernardi, P. and Rasola, A. (2007) Calcium and cell death: the mitochondrial connection. *Subcell Biochem.* 45, 481–506.
- 115 Bertipaglia, I. and Carafoli, E. (2007) Calpains and human disease. *Subcell Biochem.* 45, 29–53.
- 116 Gutiérrez, J. M., Arce, V., Brenes, F. and Chaves, F. (1990) Changes in myofibrillar components after skeletal muscle necrosis induced by a myotoxin isolated from the venom of the snake *Bothrops asper*. *Exp. Mol. Pathol.* 52, 25–36.
- 117 Vater, R., Cullen, M. J. and Harris, J. B. (1992) The fate of desmin and titin during the degeneration and regeneration of the soleus muscle of the rat. *Acta Neuropathol.* 84, 278–288.
- 118 Teixeira, C. F. P., Zamuner, S. R., Zuliani, J. P., Fernandes, C. M., Cruz-Hofling, M. A., Fernandes, I., Chaves, F. and Gutiérrez, J. M. (2003) Neutrophils do not contribute to local tissue damage, but play a key role in skeletal muscle regeneration, in mice injected with *Bothrops asper* snake venom. *Muscle & Nerve* 28, 449–459.
- 119 Herkert, M., Shakhman, O., Schweins, E. and Becker, C. M. (2001) Beta-bungarotoxin is a potent inducer of apoptosis in cultured rat neurons by receptor-mediated internalization. *Eur. J. Neurosci.* 14, 821–828.
- 120 Neco, P., Rossetto, O., Gil, A., Montecucco, C. and Gutiérrez, L. M. (2003) Taipoxin induces F-actin fragmentation and enhances release of catecholamines in bovine chromaffin cells. *J. Neurochem.* 85, 329–337.
- 121 Petrovic, U., Sribar, J., Paris, A., Rupnik, M., Krzan, M., Vardjan, N., Gubensek, F., Zorec, R. and Krizaj, I. (2004) Armodytoxin, a neurotoxic secreted phospholipase A₂, can act in the cytosol of the nerve cell. *Biochem. Biophys. Res. Commun.* 324, 981–985.
- 122 Wagner, G. M., Mart, P. E. and Kelly, R. B. (1974) Beta-bungarotoxin inhibition of calcium accumulation by rat brain mitochondria. *Biochem. Biophys. Res. Commun.* 58, 475–481.
- 123 Nicholls, D., Snelling, R. and Dolly, O. (1985) Bioenergetic actions of beta-bungarotoxin, dendrotoxin and bee-venom phospholipase A₂ on guinea-pig synaptosomes. *Biochem. J.* 229, 653–662.
- 124 Harris, J. B., Grubb, B. D., Maltin CA and Dixon R (2000) The neurotoxicity of the venom phospholipases A₂, notexin and taipoxin. *Exp. Neurol.* 161, 517–526.
- 125 Duchon, L. W., Gomez, S. and Queiroz, L. S. (1981) The neuromuscular junction of the mouse after black widow spider venom. *J. Physiol.* 316, 279–291.
- 126 Lambeau, G., Schmid-Alliana, A., Lazdunski, M. and Barhanin, J. (1990) Identification and purification of a very high affinity binding protein for toxic phospholipases A₂ in skeletal muscle. *J. Biol. Chem.* 265, 9526–9532.
- 127 Ancian, P., Lambeau, G. and Lazdunski, M. (1995) Multifunctional activity of the extracellular domain of the M-type

- (180 kDa) membrane receptor for secretory phospholipases A₂. *Biochemistry* 34, 13146–13151.
- 128 Landucci, E. C., Castro, R. C., Pereira, M. F., Cintra, A. C., Giglio, J. R., Marangoni, S., Oliveira, B., Cirino, G., Antunes, E. and de Nucci, G. (1998) Mast cell degranulation induced by two phospholipase A₂ homologues: dissociation between enzymatic and biological activities. *Eur. J. Pharmacol.* 343, 257–263.
- 129 Landucci, E. C., Toyama, M., Marangoni, S., Oliveira, B., Cirino, G., Antunes, E. and de Nucci, G. (2000) Effect of crotoptin and heparin on the rat paw oedema induced by different secretory phospholipases A₂. *Toxicon* 38, 199–208.
- 130 Melo, P. A., Homs-Brandeburgo, M. I., Giglio, J. R. and Suarez-Kurtz, G. (1993) Antagonism of the myotoxic effects of *Bothrops jararacussu* venom and bothropstoxin by polyanions. *Toxicon* 31, 285–291.
- 131 Lomonte, B., Tarkowski, A., Bagge, U. and Hanson, L. Å. (1994) Neutralization of the cytolytic and myotoxic activities of phospholipases A₂ from *Bothrops asper* snake venom by glycosaminoglycans of the heparin/heparan sulfate family. *Biochem. Pharmacol.* 47, 1509–1518.
- 132 Metz, M., Piliponsky, A. M., Chen, C. C., Lammel, V., Abrink, M., Pejler, G., Tsai, M. and Galli, S. J. (2006) Mast cells can enhance resistance to snake and honeybee venoms. *Science* 313, 526–530.
- 133 Lizano, S., Domont, G. and Perales, J. (2003) Natural phospholipase A₂ myotoxin inhibitor proteins from snakes, mammals and plants. *Toxicon* 42, 963–977.
- 134 Harris, J. B. (2003) Myotoxic phospholipases A₂ and the regeneration of skeletal muscles. *Toxicon* 42, 933–945.
- 135 Son, Y. J., Trachtenberg, J. T., Thompson, W. J. (1996) Schwann cells induce and guide sprouting and reinnervation of neuromuscular junctions. *Trends Neurosci.* 19, 280–285.
- 136 Gutiérrez, J. M., Ownby, C. L. and Odell, G. V. (1984) Skeletal muscle regeneration after myonecrosis induced by crude venom and a myotoxin from the snake *Bothrops asper* (Fer-de-Lance). *Toxicon* 22, 719–731.
- 137 Gutiérrez, J. M., Romero, M., Núñez, J., Chaves, F., Borkow, G. and Ovadia, M. (1995) Skeletal muscle necrosis and regeneration after injection of BaH1, a hemorrhagic metalloproteinase isolated from the venom of the snake *Bothrops asper* (terciopelo). *Exp. Mol. Pathol.* 62, 28–41.
- 138 Ritonja, A. and Gubensek, F. (1985) Ammodytoxin A, a highly lethal phospholipase A₂ from *Vipera ammodytes ammodytes* venom. *Biochim. Biophys. Acta* 828, 306–312.
- 139 Wu, P. F. and Chang, L. S. (2000) Genetic organization of A chain and B chain of beta-bungarotoxin from Taiwan banded krait (*Bungarus multicinctus*). A chain genes and B chain genes do not share a common origin. *Eur. J. Biochem.* 267, 4668–4675.
- 140 Kondo, K., Toda, H., Narita, K. and Lee, C. Y. (1982) Amino acid sequence of beta 2-bungarotoxin from *Bungarus multicinctus* venom. The amino acid substitutions in the B chains. *J. Biochem.* 91, 1519–1530.
- 141 Sutcliffe, M. J., Dobson, C. M. and Oswald, R. E. (1992) Solution structure of neuronal bungarotoxin determined by two-dimensional NMR spectroscopy: calculation of tertiary structure using systematic homologous model building, dynamical simulated annealing, and restrained molecular dynamics. *Biochemistry* 31, 2962–2970.
- 142 Lind, P. and Eaker, D. (1982) Amino-acid sequence of the alpha-subunit of taipoxin, an extremely potent presynaptic neurotoxin from the Australian snake taipan (*Oxyuranus s. scutellatus*). *Eur. J. Biochem.* 124, 441–447.
- 143 Pearson, J. A., Tyler, M. I., Retson, K. V. and Howden, M. E. (1993) Studies on the subunit structure of textitoxin, a potent presynaptic neurotoxin from the venom of the Australian common brown snake (*Pseudonaja textilis*). 3. The complete amino-acid sequences of all the subunits. *Biochim. Biophys. Acta* 1161, 223–229.
- 144 Halpert, J. and Eaker, D. (1975) Amino acid sequence of a presynaptic neurotoxin from the venom of *Notechis scutatus* (Australian tiger snake). *J. Biol. Chem.* 250, 6990–6997.
- 145 Westerlund, B., Nordlund, P., Uhlin, U., Eaker, D. and Eklund, H. (1992) The three-dimensional structure of noteixin, a presynaptic neurotoxic phospholipase A₂ at 2.0 Å resolution. *FEBS Lett.* 301, 159–164.
- 146 Aird, S. D., Kaiser, I. I., Lewis, R. V. and Kruggel, W. G. (1985) Rattlesnake presynaptic neurotoxins: primary structure and evolutionary origin of the acidic subunit. *Biochemistry* 24, 7054–7058.
- 147 Aird, S. D., Yates, J. R., Martino, P. A., Shabanowitz, J., Hunt, D. F. and Kaiser, I. I. (1990) The amino acid sequence of the acidic subunit B-chain of crotoxin. *Biochim. Biophys. Acta* 1040, 217–224.
- 148 Kaiser, I. I., Gutiérrez, J. M., Plummer, D., Aird, S. D. and Odell, G. V. (1990) The amino acid sequence of a myotoxic phospholipase from the venom of *Bothrops asper*. *Archs. Biochem. Biophys.* 278, 319–325.
- 149 Pereira, M. F., Novello, J. C., Cintra, A. C. O., Giglio, J. R., Landucci, E. T., Oliveira, B. and Marangoni, S. (1998) The amino acid sequence of bothropstoxin-II, an Asp-49 myotoxin from *Bothrops jararacussu* (Jararacucu) venom with low phospholipase A₂ activity. *J. Protein Chem.* 17, 381–386.
- 150 Maraganore, J. M., Merutka, G., Cho, W., Welches, W., Kézdy, F. J. and Heinrikson, R. L. (1984) A new class of phospholipases A₂ with lysine in place of aspartate 49. *J. Biol. Chem.* 259, 13839–13843.
- 151 Dhillon, D. S., Condrea, E., Maraganore, J. M., Heinrikson, R. L., Benjamin, S. and Rosenberg, P. (1987) Comparison of enzymatic and pharmacological activities of lysine-49 and aspartate-49 phospholipases A₂ from *Agkistrodon piscivorus piscivorus* snake venom. *Biochem. Pharmacol.* 36, 1723–1730.
- 152 Holland, D. R., Clancy, L. L., Muchmore, S. W., Ryde, T. J., Einspahr, H. M., Finzel, B. C., Heinrikson, R. L. and Watenpugh, K. D. (1990) The crystal structure of a lysine 49 phospholipase A₂ from the venom of the cottonmouth snake at 2.0-Å resolution. *J. Biol. Chem.* 265, 17649–17656.
- 153 Johnson, E. K. and Ownby, C. L. (1993) Isolation of a myotoxin from the venom of *Agkistrodon contortrix laticinctus* (broad-banded copperhead) and pathogenesis of myonecrosis induced by it in mice. *Toxicon* 31, 243–255.
- 154 Selistre de Araujo, H. S., White, S. P. and Ownby, C. L. (1996) cDNA cloning and sequence analysis of a lysine-49 phospholipase A₂ myotoxin from *Agkistrodon contortrix laticinctus* snake venom. *Archs. Biochem. Biophys.* 326, 21–30.
- 155 Angulo, Y., Olamendi-Portugal, T., Possani, L. D. and Lomonte, B. (2000) Isolation and characterization of myotoxin II from *Atropoides (Bothrops) nummifer* snake venom, a new Lys49 phospholipase A₂ homologue. *Int. J. Biochem. Cell Biol.* 32, 63–71.
- 156 Angulo, Y., Olamendi-Portugal, T., Alape-Giron, A., Possani, L. D. and Lomonte, B. (2002) Structural characterization and phylogenetic relationships of myotoxin II from *Atropoides (Bothrops) nummifer* snake venom, a Lys49 phospholipase A₂ homologue. *Int. J. Biochem. Cell Biol.* 34, 1268–1278.
- 157 Murakami, M. T., Melo, C. C., Angulo, Y., Lomonte, B. and Arni, R. K. (2006) Structure of myotoxin-II, a catalytically inactive Lys49 phospholipase A₂ homologue from *Atropoides nummifer* venom. *Acta Cryst. F* 62, 423–426.
- 158 Lomonte, B. and Gutiérrez, J. M. (1989) A new muscle damaging toxin, myotoxin II, from the venom of the snake *Bothrops asper* (terciopelo). *Toxicon* 27, 725–733.
- 159 Francis, B., Gutiérrez, J. M., Lomonte, B. and Kaiser, I. I. (1991) Myotoxin II from *Bothrops asper* (Terciopelo) venom is a lysine-49 phospholipase A₂. *Archs. Biochem. Biophys.* 284, 352–359.
- 160 Arni, R. K., Ward, R. J., Gutiérrez, J. M. and Tulinsky, A. (1995) Structure of a calcium-independent phospholipase-like myotoxic protein from *Bothrops asper* venom. *Acta Cryst. D* 51, 311–317.

- 161 Homsí-Brandeburgo, M. I., Queiroz, L. S., Santo-Neto, H., Rodrigues-Simioni, L. and Giglio, J. R. (1988) Fractionation of *Bothrops jararacussu* snake venom: partial chemical characterization and biological activity of bothropstoxin. *Toxicon* 26, 615–627.
- 162 Cintra, A. C. O., Marangoni, S., Oliveira, B. and Giglio, J. R. (1993) Bothropstoxin-I: amino acid sequence and function. *J. Prot. Chem.* 12, 57–64.
- 163 Murakami, M. T., Vicotia, M. M., Abrego, J. R. B., Lourenzoni, M. R., Cintra, A. C. O., Arruda, E. Z., Tomaz, M. A., Melo, P. A. and Arni, R. K. (2007) Interfacial surface charge and free accessibility to the PLA₂-active site-like region are essential requirements for the activity of Lys49 PLA₂ homologues. *Toxicon* 49, 378–387.
- 164 Soares, A. M., Rodrigues, V. M., Homsí-Brandeburgo, M. I., Toyama, M. H., Lombardi, F. R., Arni, R. K. and Giglio, J. R. (1998) A rapid procedure for the isolation of the Lys-49 myotoxin II from *Bothrops moojeni* (caissaca) venom: biochemical characterization, crystallization, myotoxic and edematogenic activity. *Toxicon* 36, 503–514.
- 165 Watanabe, L., Soares, A. M., Ward, R. J., Fontes, M. R. M. and Arni, R. K. (2005) Structural insights for fatty acid binding in a Lys49-phospholipaseA₂: crystal structure of myotoxin II from *Bothrops moojeni* complexed with stearic acid. *Biochimie* 87, 161–167.
- 166 Stábeli, R. G., Amui, S. F., Sant'Ana, C. D., Pires, M. G., Nomizo, A., Monteiro, M. C., Romão, P. R. T., Guerra-Sá, R., Vieira, C. A., Giglio, J. R., Fontes, M. R. M. and Soares, A. M. (2006) *Bothrops moojeni* myotoxin-II, a Lys49-phospholipase A₂ homologue: an example of function versatility of snake venom proteins. *Comp. Biochem. Physiol. C* 142, 371–381.
- 167 Krizaj, I., Bieber, A. L., Ritonja, A. and Gubenšek, F. (1991) The primary structure of ammodytin L, a myotoxic phospholipase A₂ homologue from *Vipera ammodytes* venom. *Eur. J. Biochem.* 202, 1165–1168.
- 168 Han, S. K., Yoon, E. T., Scott, D. L., Sigler, P. B., and Cho, W. (1997) Structural aspects of interfacial adsorption. A crystallographic and site-directed mutagenesis study of the phospholipase A₂ from the venom of *Agkistrodon piscivorus piscivorus*. *J. Biol. Chem.* 272, 3573–3582.

To access this journal online:
<http://www.birkhauser.ch/CMLS>
